Φορτώνει......
Improved Therapy by Pretargeted Radioimmunotherapy of Non-Hodgkin Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific Antibody
We examined whether a pretargeting method using a new, recombinant anti-CD20 bispecific antibody (bsMAb) followed by (90)Y-DOTA-peptide could reduce hematological toxicity yet improve therapeutic responses, compared to conventional (90)Y-anti-CD20 IgG and a chemically-conjugated bsMAb. TF4, a humani...
Αποθηκεύτηκε σε:
| Κύριοι συγγραφείς: | , , , , , , |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2008
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2585743/ https://ncbi.nlm.nih.gov/pubmed/18593929 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-08-0037 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|